drug therapy: dose-response relationship of oral mesalazine in 
inflammatory bowel disease

C. J. J. Mulder; S. J. Van Den Hazel

drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease

Clicks: 230

ID: 187596

1998

Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g). In mild to moderately active ulcerative colitis, studies also indicate that higher dosages might be more effective in inducing remission. Dose-comparing studies in Crohn's disease are even more sparse, but the available results indicate higher efficacy at higher dose levels.

Reference Key	mulder1998mediatorsdrug Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors	;C. J. J. Mulder;S. J. Van Den Hazel
Journal	polyhedron
Year	1998
DOI	10.1080/09629359891027
URL	http://dx.doi.org/10.1080/09629359891027 https://doi.org/10.1080/09629359891027
Keywords	safety pathology inflammatory bowel disease side effects drug therapy crohn's disease

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

Login to comment Register

No comments yet. Be the first to comment on this article.